Drug Trial Radar · NCT00072839
Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease
Last checked: Nov 19, 2026Latest source record: May 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Nov 12, 2003
Primary completion
Jul 28, 2005
Study completion Jul 28, 2005
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Nov 13, 2003
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine whether an investigational compound, ALX-0600, is safe and effective in treating Crohn's Disease.
Conditions
- Crohn's Disease
Interventions
ALX-0600Drug
teduglutide
placeboDrug
placebo solution injected subcutaneously
teduglutide 0.05Drug
0.05 mg/jg/d subcutaneous daily injection into thigh or abdomen
teduglutide 0.2 mgDrug
0.2 mg/kg/d subcutaneously injected into thigh or abdomen
Teduglutide 0.05 doseDrug
0.05 mg/kg/d subcutaneous daily injection into thigh or abdomen
teduglutide 0.1 mg doseDrug
0.1 mg/kg/d daily subcutaneous injection into thigh or abdomen
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary efficacy variable is the percentage of subjects who respond to treatment, defined as the percentage of subjects who are in remission (CDAI less than 150) or have a 100-point or greater reduction from baseline in CDAI score at dosing Week 8.Time frame: 8 weeks of treatment
Locations
26 sites in 2 countries. Site status is shown where the registry gives one.
Advanced Clinical Therapeutics
Tucson, Arizona
Rocky Mountain Gastroenterology
Lakewood, Colorado
Rx Trials
Washington D.C., District of Columbia
Clinical Trials Management of Boca Raton
Boca Raton, Florida
Clinical Research of West Florida
Clearwater, Florida
Venture Research
North Miami Beach, Florida
Visions Clinical Research - Sarasota
Sarasota, Florida
Emory University School of Medicine
Atlanta, Georgia
Pinnacle Trials
Atlanta, Georgia
Saint Joseph's Health System
Atlanta, Georgia
Northwestern University School of Medicine
Chicago, Illinois
University of Chicago
Chicago, Illinois
University of Louisville
Louisville, Kentucky
Long Island Clinical Research Associates
Great Neck, New York
Asher Kornbluth, MD, PC
New York, New York
Cleveland Clinic Foundation
Cleveland, Ohio
Allegheny General Hospital-Allegheny Ctr for Digestive Diseases
Pittsburgh, Pennsylvania
Methodist Hospital/Baylor University
Houston, Texas
University of Utah
Salt Lake City, Utah
McGuire DVAMC
Richmond, Virginia
Dean Foundation Research Center
Madison, Wisconsin
Vancouver General Hospital
Vancouver, British Columbia, Canada
Odyssey Research
Victoria, British Columbia, Canada
Health Sciences Center
Winnipeg, Manitoba, Canada
Queen Elizabeth II Health Sciences
Halifax, Nova Scotia, Canada
Life Screening Centres
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.